THU0416 Prevalence of Comorbidities and Risk Factors in Spondyloarthritis in Latin America: A Comparative Study with General Population: Data from The Multinational Asas-Comospa Study
BackgroundIncreased risk of some comorbidities has been reported in spondyloarthritis (SpA). Knowledge about the prevalence and data related to these comorbidities and risk factors in Latin America is limited.ObjectivesTo determine the prevalence of several comorbidities and risk factors for these c...
Gespeichert in:
Veröffentlicht in: | Annals of the rheumatic diseases 2016-06, Vol.75 (Suppl 2), p.339-339 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 339 |
---|---|
container_issue | Suppl 2 |
container_start_page | 339 |
container_title | Annals of the rheumatic diseases |
container_volume | 75 |
creator | Bautista-Molano, W. Landewé, R. Moltό, A. Burgos-Vargas, R. Maldonado-Cocco, J. Valle-Oñate, R. van der Heijde, D. |
description | BackgroundIncreased risk of some comorbidities has been reported in spondyloarthritis (SpA). Knowledge about the prevalence and data related to these comorbidities and risk factors in Latin America is limited.ObjectivesTo determine the prevalence of several comorbidities and risk factors for these comorbidities in patients with SpA in three Latin American countries, and to compare this prevalence with the rates in the general population investigating whether the prevalence is increased.MethodsData of 390 consecutive patients with SpA enrolled in the international cross-sectional ASAS-COMOSPA study from Argentina, Colombia and Mexico were analysed. The prevalence rates (95% CI) of arterial hypertension (AHT), tuberculosis (TB), and malignancies (colon, melanoma, lung, lymphoma, prostate, cervix and breast) were estimated with continuity correction according to the method described by Wilson. The data from Colombian general population (adjusted per gender and age group) were obtained from the CARMELA study for AHT, from the National Health Surveillance Public System for TB and HBV and from the GLOBOCAN project for malignancies. The prevalence (95% IC) in SpA patients was compared with the prevalence rates in the Colombian general population by calculating age and gender-specific prevalences for AHT, TB and HBV, and calculating gender-specific prevalences for malignancies. SPSS Statistics 22 was used to perform the statistical analysis.ResultsIn total 64% were male, mean age of 45 (14.7) years and disease duration of 7.0 (8.1) years. The most common comorbidities were AHT (25.3%), hypercholesterolemia (21.8%), osteoporosis (9.4%) and gastrointestinal ulcer (7.8%). The prevalence of AHT was 25.3% (95% CI 21.2 to 29.4) and was significantly higher compared with the general population 13.4% (95% CI 11.5 to 15.2). The overall prevalence of TB was 3.33% (95% CI 1.8 to 5.7) and the prevalence of HBV infection was 1.03% (95% IC 0.3 to 2.7), both increased as compared with the general population (0.03% and 0.01% respectively). There was not an increased prevalence of cancers compared with general population.ConclusionsIn patients with SpA, we found a higher prevalence of hypertension, tuberculosis and hepatitis B infections in three Latin America countries as compared with general population data. A systematic evaluation and screening of these comorbidities and risk factors may help to properly monitor and detect these conditions in SpA patients.ReferencesMolto A, et |
doi_str_mv | 10.1136/annrheumdis-2016-eular.1814 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1901804340</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322509357</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1270-a6b8082849131c23d35cb4f309916a7dacc6095a35a2ca3612e3e841d36bf3873</originalsourceid><addsrcrecordid>eNqVkcGO0zAYhC0EEmXhHSztOYv_2HWd5VQVdhepiBXbPVt_HEd1SeJgO4t648JD8To8CU7LgSsXWx7PjEb6CLkEdgXA5VschrC3U9-4WJQMZGGnDsMVKBDPyAKEVFmW7DlZMMZ4ISq5eklexXjIT6ZALciv3d0jEyB___h5H-wTdnYwlvqWbnzvQ-0al5yNFIeGfnHxK71Bk3yI1A30YfRDc-w8hrQP2XYSt5jyue5tcAav6XruGTFk9cnShzQ1R_rdpT29tYMN2NF7P-bJyfnhmr7HhLQNvqe7vaWfpi5Xnb6ybx0xFvOmOOK55zV50WIX7Zu_9wV5vPmw29wV28-3HzfrbVFDuWIFyloxVSpRAQdT8oYvTS1azqoKJK4aNEayaol8iaVBLqG03CoBDZd1y9WKX5DLc-8Y_LfJxqQPfgp5U9RQMVBMcMGy693ZZYKPMdhWj8H1GI4amJ5Z6X9Y6ZmVPrHSM6uclud03R_-K_gH9oqi_A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901804340</pqid></control><display><type>article</type><title>THU0416 Prevalence of Comorbidities and Risk Factors in Spondyloarthritis in Latin America: A Comparative Study with General Population: Data from The Multinational Asas-Comospa Study</title><source>BMJ Journals - NESLi2</source><creator>Bautista-Molano, W. ; Landewé, R. ; Moltό, A. ; Burgos-Vargas, R. ; Maldonado-Cocco, J. ; Valle-Oñate, R. ; van der Heijde, D.</creator><creatorcontrib>Bautista-Molano, W. ; Landewé, R. ; Moltό, A. ; Burgos-Vargas, R. ; Maldonado-Cocco, J. ; Valle-Oñate, R. ; van der Heijde, D.</creatorcontrib><description>BackgroundIncreased risk of some comorbidities has been reported in spondyloarthritis (SpA). Knowledge about the prevalence and data related to these comorbidities and risk factors in Latin America is limited.ObjectivesTo determine the prevalence of several comorbidities and risk factors for these comorbidities in patients with SpA in three Latin American countries, and to compare this prevalence with the rates in the general population investigating whether the prevalence is increased.MethodsData of 390 consecutive patients with SpA enrolled in the international cross-sectional ASAS-COMOSPA study from Argentina, Colombia and Mexico were analysed. The prevalence rates (95% CI) of arterial hypertension (AHT), tuberculosis (TB), and malignancies (colon, melanoma, lung, lymphoma, prostate, cervix and breast) were estimated with continuity correction according to the method described by Wilson. The data from Colombian general population (adjusted per gender and age group) were obtained from the CARMELA study for AHT, from the National Health Surveillance Public System for TB and HBV and from the GLOBOCAN project for malignancies. The prevalence (95% IC) in SpA patients was compared with the prevalence rates in the Colombian general population by calculating age and gender-specific prevalences for AHT, TB and HBV, and calculating gender-specific prevalences for malignancies. SPSS Statistics 22 was used to perform the statistical analysis.ResultsIn total 64% were male, mean age of 45 (14.7) years and disease duration of 7.0 (8.1) years. The most common comorbidities were AHT (25.3%), hypercholesterolemia (21.8%), osteoporosis (9.4%) and gastrointestinal ulcer (7.8%). The prevalence of AHT was 25.3% (95% CI 21.2 to 29.4) and was significantly higher compared with the general population 13.4% (95% CI 11.5 to 15.2). The overall prevalence of TB was 3.33% (95% CI 1.8 to 5.7) and the prevalence of HBV infection was 1.03% (95% IC 0.3 to 2.7), both increased as compared with the general population (0.03% and 0.01% respectively). There was not an increased prevalence of cancers compared with general population.ConclusionsIn patients with SpA, we found a higher prevalence of hypertension, tuberculosis and hepatitis B infections in three Latin America countries as compared with general population data. A systematic evaluation and screening of these comorbidities and risk factors may help to properly monitor and detect these conditions in SpA patients.ReferencesMolto A, et al. Ann Rheum Dis 2015 Oct 21 pii: annrheumdis-2015–208174Gherghe AM, et al. RMD Open 2015 Sept 14;1(1):e000128Hernández-Hernández R, J Hypertens 2010, 28:24–34Disclosure of InterestNone declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2016-eular.1814</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><ispartof>Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.339-339</ispartof><rights>2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2016 (c) 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/75/Suppl_2/339.2.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/75/Suppl_2/339.2.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,3196,23571,27924,27925,77600,77631</link.rule.ids></links><search><creatorcontrib>Bautista-Molano, W.</creatorcontrib><creatorcontrib>Landewé, R.</creatorcontrib><creatorcontrib>Moltό, A.</creatorcontrib><creatorcontrib>Burgos-Vargas, R.</creatorcontrib><creatorcontrib>Maldonado-Cocco, J.</creatorcontrib><creatorcontrib>Valle-Oñate, R.</creatorcontrib><creatorcontrib>van der Heijde, D.</creatorcontrib><title>THU0416 Prevalence of Comorbidities and Risk Factors in Spondyloarthritis in Latin America: A Comparative Study with General Population: Data from The Multinational Asas-Comospa Study</title><title>Annals of the rheumatic diseases</title><description>BackgroundIncreased risk of some comorbidities has been reported in spondyloarthritis (SpA). Knowledge about the prevalence and data related to these comorbidities and risk factors in Latin America is limited.ObjectivesTo determine the prevalence of several comorbidities and risk factors for these comorbidities in patients with SpA in three Latin American countries, and to compare this prevalence with the rates in the general population investigating whether the prevalence is increased.MethodsData of 390 consecutive patients with SpA enrolled in the international cross-sectional ASAS-COMOSPA study from Argentina, Colombia and Mexico were analysed. The prevalence rates (95% CI) of arterial hypertension (AHT), tuberculosis (TB), and malignancies (colon, melanoma, lung, lymphoma, prostate, cervix and breast) were estimated with continuity correction according to the method described by Wilson. The data from Colombian general population (adjusted per gender and age group) were obtained from the CARMELA study for AHT, from the National Health Surveillance Public System for TB and HBV and from the GLOBOCAN project for malignancies. The prevalence (95% IC) in SpA patients was compared with the prevalence rates in the Colombian general population by calculating age and gender-specific prevalences for AHT, TB and HBV, and calculating gender-specific prevalences for malignancies. SPSS Statistics 22 was used to perform the statistical analysis.ResultsIn total 64% were male, mean age of 45 (14.7) years and disease duration of 7.0 (8.1) years. The most common comorbidities were AHT (25.3%), hypercholesterolemia (21.8%), osteoporosis (9.4%) and gastrointestinal ulcer (7.8%). The prevalence of AHT was 25.3% (95% CI 21.2 to 29.4) and was significantly higher compared with the general population 13.4% (95% CI 11.5 to 15.2). The overall prevalence of TB was 3.33% (95% CI 1.8 to 5.7) and the prevalence of HBV infection was 1.03% (95% IC 0.3 to 2.7), both increased as compared with the general population (0.03% and 0.01% respectively). There was not an increased prevalence of cancers compared with general population.ConclusionsIn patients with SpA, we found a higher prevalence of hypertension, tuberculosis and hepatitis B infections in three Latin America countries as compared with general population data. A systematic evaluation and screening of these comorbidities and risk factors may help to properly monitor and detect these conditions in SpA patients.ReferencesMolto A, et al. Ann Rheum Dis 2015 Oct 21 pii: annrheumdis-2015–208174Gherghe AM, et al. RMD Open 2015 Sept 14;1(1):e000128Hernández-Hernández R, J Hypertens 2010, 28:24–34Disclosure of InterestNone declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkcGO0zAYhC0EEmXhHSztOYv_2HWd5VQVdhepiBXbPVt_HEd1SeJgO4t648JD8To8CU7LgSsXWx7PjEb6CLkEdgXA5VschrC3U9-4WJQMZGGnDsMVKBDPyAKEVFmW7DlZMMZ4ISq5eklexXjIT6ZALciv3d0jEyB___h5H-wTdnYwlvqWbnzvQ-0al5yNFIeGfnHxK71Bk3yI1A30YfRDc-w8hrQP2XYSt5jyue5tcAav6XruGTFk9cnShzQ1R_rdpT29tYMN2NF7P-bJyfnhmr7HhLQNvqe7vaWfpi5Xnb6ybx0xFvOmOOK55zV50WIX7Zu_9wV5vPmw29wV28-3HzfrbVFDuWIFyloxVSpRAQdT8oYvTS1azqoKJK4aNEayaol8iaVBLqG03CoBDZd1y9WKX5DLc-8Y_LfJxqQPfgp5U9RQMVBMcMGy693ZZYKPMdhWj8H1GI4amJ5Z6X9Y6ZmVPrHSM6uclud03R_-K_gH9oqi_A</recordid><startdate>201606</startdate><enddate>201606</enddate><creator>Bautista-Molano, W.</creator><creator>Landewé, R.</creator><creator>Moltό, A.</creator><creator>Burgos-Vargas, R.</creator><creator>Maldonado-Cocco, J.</creator><creator>Valle-Oñate, R.</creator><creator>van der Heijde, D.</creator><general>BMJ Publishing Group LTD</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201606</creationdate><title>THU0416 Prevalence of Comorbidities and Risk Factors in Spondyloarthritis in Latin America: A Comparative Study with General Population: Data from The Multinational Asas-Comospa Study</title><author>Bautista-Molano, W. ; Landewé, R. ; Moltό, A. ; Burgos-Vargas, R. ; Maldonado-Cocco, J. ; Valle-Oñate, R. ; van der Heijde, D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1270-a6b8082849131c23d35cb4f309916a7dacc6095a35a2ca3612e3e841d36bf3873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bautista-Molano, W.</creatorcontrib><creatorcontrib>Landewé, R.</creatorcontrib><creatorcontrib>Moltό, A.</creatorcontrib><creatorcontrib>Burgos-Vargas, R.</creatorcontrib><creatorcontrib>Maldonado-Cocco, J.</creatorcontrib><creatorcontrib>Valle-Oñate, R.</creatorcontrib><creatorcontrib>van der Heijde, D.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bautista-Molano, W.</au><au>Landewé, R.</au><au>Moltό, A.</au><au>Burgos-Vargas, R.</au><au>Maldonado-Cocco, J.</au><au>Valle-Oñate, R.</au><au>van der Heijde, D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>THU0416 Prevalence of Comorbidities and Risk Factors in Spondyloarthritis in Latin America: A Comparative Study with General Population: Data from The Multinational Asas-Comospa Study</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2016-06</date><risdate>2016</risdate><volume>75</volume><issue>Suppl 2</issue><spage>339</spage><epage>339</epage><pages>339-339</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundIncreased risk of some comorbidities has been reported in spondyloarthritis (SpA). Knowledge about the prevalence and data related to these comorbidities and risk factors in Latin America is limited.ObjectivesTo determine the prevalence of several comorbidities and risk factors for these comorbidities in patients with SpA in three Latin American countries, and to compare this prevalence with the rates in the general population investigating whether the prevalence is increased.MethodsData of 390 consecutive patients with SpA enrolled in the international cross-sectional ASAS-COMOSPA study from Argentina, Colombia and Mexico were analysed. The prevalence rates (95% CI) of arterial hypertension (AHT), tuberculosis (TB), and malignancies (colon, melanoma, lung, lymphoma, prostate, cervix and breast) were estimated with continuity correction according to the method described by Wilson. The data from Colombian general population (adjusted per gender and age group) were obtained from the CARMELA study for AHT, from the National Health Surveillance Public System for TB and HBV and from the GLOBOCAN project for malignancies. The prevalence (95% IC) in SpA patients was compared with the prevalence rates in the Colombian general population by calculating age and gender-specific prevalences for AHT, TB and HBV, and calculating gender-specific prevalences for malignancies. SPSS Statistics 22 was used to perform the statistical analysis.ResultsIn total 64% were male, mean age of 45 (14.7) years and disease duration of 7.0 (8.1) years. The most common comorbidities were AHT (25.3%), hypercholesterolemia (21.8%), osteoporosis (9.4%) and gastrointestinal ulcer (7.8%). The prevalence of AHT was 25.3% (95% CI 21.2 to 29.4) and was significantly higher compared with the general population 13.4% (95% CI 11.5 to 15.2). The overall prevalence of TB was 3.33% (95% CI 1.8 to 5.7) and the prevalence of HBV infection was 1.03% (95% IC 0.3 to 2.7), both increased as compared with the general population (0.03% and 0.01% respectively). There was not an increased prevalence of cancers compared with general population.ConclusionsIn patients with SpA, we found a higher prevalence of hypertension, tuberculosis and hepatitis B infections in three Latin America countries as compared with general population data. A systematic evaluation and screening of these comorbidities and risk factors may help to properly monitor and detect these conditions in SpA patients.ReferencesMolto A, et al. Ann Rheum Dis 2015 Oct 21 pii: annrheumdis-2015–208174Gherghe AM, et al. RMD Open 2015 Sept 14;1(1):e000128Hernández-Hernández R, J Hypertens 2010, 28:24–34Disclosure of InterestNone declared</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/annrheumdis-2016-eular.1814</doi><tpages>1</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-4967 |
ispartof | Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.339-339 |
issn | 0003-4967 1468-2060 |
language | eng |
recordid | cdi_proquest_journals_1901804340 |
source | BMJ Journals - NESLi2 |
title | THU0416 Prevalence of Comorbidities and Risk Factors in Spondyloarthritis in Latin America: A Comparative Study with General Population: Data from The Multinational Asas-Comospa Study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T11%3A49%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=THU0416%E2%80%85Prevalence%20of%20Comorbidities%20and%20Risk%20Factors%20in%20Spondyloarthritis%20in%20Latin%20America:%20A%20Comparative%20Study%20with%20General%20Population:%20Data%20from%20The%20Multinational%20Asas-Comospa%20Study&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Bautista-Molano,%20W.&rft.date=2016-06&rft.volume=75&rft.issue=Suppl%202&rft.spage=339&rft.epage=339&rft.pages=339-339&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2016-eular.1814&rft_dat=%3Cproquest_cross%3E4322509357%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901804340&rft_id=info:pmid/&rfr_iscdi=true |